Re: Risk/benefit assessment of tamoxifen to prevent breast cancer-still a work in progress?
Gail
M H
MH
Costantino
J P
JP
Bryant
J
J
Croyle
R
R
Freedman
L
L
Helzlsouer
K
K
Vogel
V
V
D001741:Black or African American / Q000706:statistics & numerical data*; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000453:epidemiology* / Q000401:mortality / Q000517:prevention & control*; D020847:Estrogen Receptor Modulators / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015994:Incidence; D012306:Risk; D018570:Risk Assessment; D013629:Tamoxifen / Q000627:therapeutic use*; D014481:United States / Q000453:epidemiology
D016588:Anticarcinogenic Agents; D020847:Estrogen Receptor Modulators; D013629:Tamoxifen